The medication is generally used in situations involving certain distressing symptoms related to acute physiological changes. It is applied when short-term symptomatic assistance is needed to address severe symptomatic manifestations. Nikethamide, widely known by its former trade name Coramine, is associated with historical use in situations involving heightened systemic burden related to respiratory compromise.

Key Therapeutic Domains

The supportive use of Coramine Glucose is considered relevant in clinical settings marked by acute or disruptive symptom patterns. It focuses on symptoms of depressed breathing effort and acute energy deprivation, and is relevant in conditions marked by increased physiological stress, such as severe intoxication or circulatory failure. The benefit contributes to easing the overall symptom load during periods of heightened symptoms.

“It is applied across domains where additional symptomatic support is needed to manage symptoms that interfere with daily comfort.”

Addressing Acute Symptom Clusters

This medication plays a role in managing symptoms that create noticeable physiological strain. It is commonly used when symptom clusters, such as breathing decline coupled with extreme weakness, appear suddenly or fluctuate. Its use generally provides supportive relief in scenarios requiring temporary assistance, assisting with maintaining functional stability when symptoms are more noticeable.

Fact Focus: The medication is relevant for easing symptoms associated with severe breathing difficulty and extreme systemic weakness.

Who can and cannot use Coramine Glucose?

The official eligibility profile for Coramine Glucose is strictly defined by regulatory authorities based on the component risks. The medicine is contraindicated and must not be used in individuals with clinically significant hyperglycemia, known hypersensitivity to dextrose or corn products, or existing severe dehydration. Patients with active intracranial or intraspinal hemorrhage are also ineligible, particularly for high-concentration solutions.

Conditional use and close monitoring are required for specific populations. Patients with Impaired Renal Function, Cardiac or Pulmonary Failure, or a history of Diabetes Mellitus must be treated with caution due to the risk of fluid and metabolic imbalances.

Regarding age, use in neonates and low-birth-weight infants is highly restricted and requires specialized observation. Geriatric patients must be closely monitored for hyponatremia. The medicine should be used in pregnant and breastfeeding women only if the clinical need is clear, as safety has not been fully established in regulatory labeling.

The interaction profile for Coramine Glucose is governed by the pharmacodynamic conflicts and prohibitions related to its two active components. Regulatory documents classify the co-administration of the Nikethamide component with Monoamine Oxidase Inhibitors (MAOIs) as contraindicated due to the official risk of additive central nervous system (CNS) stimulation and severe sympathetic reactions. Combining it with Indirect Sympathomimetic Agents is also strictly prohibited. The Dextrose component has a formally documented pharmacodynamic antagonism with Antidiabetic Agents, including insulin and sulfonylureas. This conflict compromises the glucose-lowering efficacy of the antidiabetic medicine, a clinically significant interaction documented in official labeling. Officially documented additive effects exist with other CNS Stimulants and substances that lower the seizure threshold, such as High-Dose Theophylline. This interaction increases the official risk of convulsions due to additive CNS excitation. The profile notes a counteraction with CNS Depressants (e.g., opioids), where the respiratory stimulant effect opposes the central respiratory depression. Furthermore, Alcohol (Ethanol) is documented to complicate or enhance the CNS effects of Nikethamide. No explicit mandatory time-separation rules, CYP-mediated metabolic interactions, or specific population-based restrictions are prominently cited in the primary regulatory warnings.

How Coramine Glucose Works

Coramine Glucose exerts its effects through a multi-target mechanism involving its two primary components: nikethamide and glucose.

Central Respiratory Stimulation

Nikethamide acts as a central nervous system (CNS) stimulant. Its pharmacodynamic activity involves direct interaction with the chemoreceptors of the carotid body and the vasomotor center in the medulla oblongata. This binding and agonistic effect increases the sensitivity of these central and peripheral regulators to carbon dioxide (CO2 ). The resulting neural cascade modulates the respiratory rhythm generator, leading to an elevated respiratory drive. This physiological consequence is characterized by an increase in both the frequency and the tidal volume of respiration.

Metabolic and Cardiac Effects

Nikethamide also produces a direct, though minor, stimulatory effect on the myocardium. Concurrently, the glucose component provides a readily available source of ATP precursors via the glycolytic pathway. This metabolic substrate is utilized by the myocardium and skeletal muscles to maintain cellular energy homeostasis, particularly under conditions of increased metabolic demand.

How Coramine Glucose is Used: Official Administration Guidelines

Coramine Glucose is administered according to a specific protocol designed for rapid intervention in acute clinical settings. The medicine is primarily supplied as an aqueous solution for intravenous (IV) infusion, although an oral route is documented as a permissible administration path for the solution form. The high concentration of the Dextrose component dictates strict adherence to administration procedures.

For adults, the typical initial dose is prescribed as 10 to 25 grams of Dextrose, which corresponds to 20 to 50 mL of a 50% solution. This constitutes an intermittent, as-needed regimen; the administration is strictly event-driven and is repeated only if warranted by subsequent clinical assessment.

The administration requires specialized conditions: the solution must be infused slowly to manage the hypertonicity of the high-concentration formula. Furthermore, central venous access is preferred, particularly for pediatric patients, to mitigate the risk of local irritation. The maximum administration rate for the Dextrose component should not exceed 0.5 g/kg of body weight per hour for adults and adolescents 12 years and older. Importantly, the hypertonic solution must not be administered via subcutaneous or intramuscular injection. This stringent procedural structure defines its use as a standardized, short-term, medically supervised intervention.

Coramine Glucose: Research Evidence Overview

Evidence Supporting Use in Acute Respiratory Depression

Research exploring the use of Coramine Glucose for breathing difficulties is primarily focused on the stimulant component, Nikethamide. Studies examining this use were largely conducted as historical observational studies and research examined changes in the body’s central breathing control. Outcomes monitored included changes in respiratory rate and tidal volume, along with shifts in arterial Pco2 levels and general Central Nervous System (CNS) alertness. These historical studies described patterns observed during the study period, where administration was associated with short-term, acute changes in breathing mechanics. The evidence available for this application is considered limited and stems from older research that often utilized small populations.

Evidence for Use in Situations Requiring Combined Acute Support

The fixed-dose combination was evaluated in research examining dual component support during acute systemic crises. These observations were intended to examine the simultaneous effects of the stimulant component on breathing and the Dextrose component on outcomes related to acute energy supply. Findings describe patterns observed in these historical studies, where the combination was applied in settings where breathing effort and acute energy supply were the focus of observation. However, there is limited information available from dedicated modern research specifically designed to evaluate the combined research effect.

Study Landscape and Key Research Gaps

The overall evidence base for Coramine Glucose appears to have low certainty. The studies monitored were primarily historical observational designs rather than contemporary, large-scale Randomized Controlled Trials. The findings reflect specific conditions under which they were conducted, often predating established medical practices. A primary research limitation is the widely cited finding that the dose associated with the intended effects may be very close to the dose that causes serious adverse reactions, which restricts the potential study of the stimulant component.

Long-Term Outcomes and Specific Populations

Studies have primarily been conducted during periods of increased symptom activity and have been limited to very short-term follow-up durations. Long-term effects are not fully established. Evidence focusing on the effects in special populations, such as pediatric patients, is also very limited, with research focused on examining susceptibility rather than comparative efficacy. The current evidence contributes to the broader understanding of historical pharmacological agents but does not determine its place in modern treatment protocols.

Key Studies & References

1. Uses of Nikethamid (Review of Historical Indications and Modern Safety Profile)

Common questions about Coramine Glucose (FAQ)

Q: Do you feel the effects of Coramine Glucose immediately?

Regulatory documents indicate the solution is designed for rapid intervention and is often administered intravenously to ensure rapid systemic delivery, which is intended to support rapid intervention in acute settings. The actual onset time can vary based on the specific route and clinical circumstances.

Q: Is Coramine Glucose suitable for children?

Official administration guidelines note that its use in neonates and low-birth-weight infants is highly restricted and requires specialized observation. Official guidelines mention considerations for pediatric patients, such as the preferred use of central venous access, and the limitations for very young patients are clearly documented in official product information.

Q: Does Coramine Glucose have known interactions with common cold and flu medications?

The official warnings state that the stimulant component, Nikethamide, must not be co-administered with Indirect Sympathomimetic Agents and has additive effects with other CNS Stimulants. Since some over-the-counter cold and flu medications may contain these classes of agents, official documents describe a need for caution due to potential additive effects.

Q: Can Coramine Glucose be used by someone with a history of heart problems?

Official documentation indicates that caution and close monitoring are necessary for patients with Cardiac or Pulmonary Failure. Furthermore, the medicine is contraindicated in patients with conditions such as severe, uncontrolled hypertension or pheochromocytoma, where central stimulation could pose a danger.

Q: Has Coramine Glucose been studied in older adults (geriatric population)?

Regulatory documents describe that Geriatric patients require close monitoring for potential issues such as hyponatremia and fluid imbalances. This requirement for monitoring suggests that regulatory knowledge and specific usage considerations exist for this older patient population.

Q: Can Coramine Glucose expire and become less effective?

Official guidelines describe that unused or expired medication is to be discarded and that the product should not be administered if the container seal is not intact or if the solution shows signs of cloudiness or precipitate. This is standard guidance for maintaining product quality.

Q: Why do some forums discuss Coramine Glucose in relation to physical performance?

Regulatory texts classify the Nikethamide component as a Central and Respiratory Stimulant. Additionally, the Glucose component provides a readily available energy substrate to muscles, which relates to the body's energy demands during physical activity.

Q: Is Coramine Glucose mentioned in research related to cognitive function?

Historical research evidence for the medicine's stimulant component has included monitoring of Central Nervous System (CNS) alertness as an outcome. CNS alertness is a factor related to cognitive effects.

Q: What are the ingredients besides the active Coramine and Glucose?

The official product labeling for the solution formulation includes inactive components, also known as excipients. These typically consist of Water for Injection and agents like Hydrochloric Acid and/or Sodium Hydroxide, which are used to adjust and maintain the solution's correct pH level.

Q: Is it safe to take Coramine Glucose if I am also taking an antidepressant?

Official product information states that the medicine is contraindicated with Monoamine Oxidase Inhibitors (MAOIs), which are a class of antidepressants. Official information indicates that other antidepressants classified as CNS Stimulants require caution due to the risk of additive central nervous system effects.

Q: Is there a special form (e.g., liquid, tablet) that works fastest?

The official administration guidelines emphasize that the solution administered via intravenous (IV) infusion is the intended route for rapid intervention. This information describes the IV route as the intended fastest method of delivery for clinical purposes.

Q: Does taking Coramine Glucose affect your sleep cycle?

The medicine acts as a CNS stimulant (it stimulates the central nervous system). Documented side effects of this action include restlessness and anxiety, which are types of effects that can disrupt the normal sleep cycle.

Q: Does Coramine Glucose require a prescription in most countries?

Regulatory status varies by region. The injectable form is typically highly regulated. However, in some countries, Nikethamide combined with glucose is listed as available in non-injectable forms as an over-the-counter product, indicating non-prescription availability in certain regions.

Q: How long does the effect of Coramine Glucose usually last?

Pharmacokinetic data provides information on how the body processes the drug. This data indicates the elimination half-life for the Nikethamide component is approximately 0.5 hours (30 minutes).

Q: How is the safety of Coramine Glucose classified by major health agencies?

The Nikethamide component is categorized as a Central Stimulant. Due to these properties, it is listed as a banned substance by the World Anti-Doping Agency (WADA).

Q: Does the medicine come in different strengths?

Official product labels show that the Dextrose component is commercially available in multiple concentrations, such as both 10% and 50% solutions, depending on the specific product formulation.

Q: Has Coramine Glucose been recalled in any regions recently?

While the specific fixed-combination drug may not have a recent recall, related Dextrose Injection products (a component of the drug) have been subject to voluntary recalls in the past due to issues such as the presence of particulate matter.

How to Store and Dispose of Coramine Glucose (Dextrose Injection)

The official storage and disposal requirements for this medication, often formulated as Dextrose Injection, USP, are defined by regulatory documents to maintain product quality and sterility.

Storage Requirements

Disposal Instructions

This medication is packaged for single-use only. Any portion of the solution remaining in the single-dose container must be discarded immediately after use. Unused or expired medication should be disposed of according to local guidelines, often involving official drug take-back programs.